康基医疗2023年度报告
康基医疗控股有限公司2023年度报告1 Contents 目录 2 Chairman’sStatement 董事长致辞 4 CorporateInformation 公司资料 6 FinancialHighlights 财务摘要 8 ManagementDiscussionandAnalysis 管理层讨论与分析 26 DirectorsandSeniorManagement 董事及高级管理层 37 ReportoftheDirectors 董事会报告 64 CorporateGovernanceReport 企业管治报告 84 Environmental,SocialandGovernanceReport 环境、社会及管治报告 164 IndependentAuditor’sReport 独立核数师报告 172 ConsolidatedStatementofProfitorLossandOtherComprehensiveIncome 综合损益及其他全面收益表 174 ConsolidatedStatementofFinancialPosition 综合财务状况表 176 ConsolidatedStatementofChangesinEquity 综合权益变动表 178 ConsolidatedStatementofCashFlows 综合现金流量表 181 NotestoFinancialStatements 财务报表附注 281 Definition 释义 Chairman’sStatement 董事长致辞 DearShareholders, In2023,withtheliftingofCOVID-19restrictions,China’soveralleconomicandbusinessactivitiescontinuedtorecoversteadily,withpatientflowandsurgicalvolumegraduallyrebounded,whichledtoanincreaseintheendmarketdemandforourproducts,andasignificantincreaseinboththedomesticandinternationalbusinesses.KangjiMedicalachievedoperatingrevenueofRMB926.0millionin2023,representingayear-on-yeargrowthofapproximately17.8%.Thenon-HKFRSadjustednetprofitattributabletoownersoftheparentfortheReportingPeriodwasRMB504.0million,representingayear-on-yeargrowthofapproximately5.3%. KangjiMedical,asaleadingenterpriseinthefieldofminimallyinvasivesurgerydeviceproductsinChina,alwaysadherestoandpracticestheclinical-orientedthinkingof“originatingfromclinicalpractice,usedforclinicalpractice”andtheproductR&Dconceptof“co-creationandco-constructionwithindustry,academia,andresearch”.Wefocusontheminimallyinvasivesurgeryfieldandinsistonprovidingcomprehensive,high-quality,reliable,andaccessibleoverallminimallyinvasivesurgicalsolutionsfordoctorsandpatientsinChinaandaroundtheworld,wherewestrivetomakemeaningfulcontributionstotheadvancementofminimallyinvasivesurgicaltechnology. 尊敬的各位股东： 着增民币长。2023年，康基医疗实现营业收入人 2济0及23商年，业随活着动疫持情续防稳控定的复放苏开，，患中者国流整量体经及手品术的量需逐求渐增回加，升国，内带及动国终际端业市务场均对获我得们显产 5.3%。 期内9的2母6.0公百司万拥元有，人同应比占增非长《约香1港7.8财%务；报告准比则增》长调约整后的纯利人民币504.0百万元，同 作始终为秉中承国与微实创践外“科源器于临械床的，龙用头于，临康床基”医的疗临床理导念，向深思耕维微、“创产外学科研手共术创领共域建，”为的中产国品及研发全球及的微生创和外患科者手提术供整全体面解、决优方质案、，可竭靠力、可为中有的国贡乃献至。全球微创外科技术的进步做出应 2KangjiMedicalHoldingsLimited2023AnnualReport Chairman’sStatement 董事长致辞 In2023,wesuccessfullyorganisedandcarriedoutmanythematicacademicpromotionconferencesandtrainingsessions.Theseactivitiescovereddifferenthighlightsrangingfromproduct-specificevents,surgery-specifictrainingstothematicconferencesinclinicalfields.Forexample,wehaveestablishedsingle-portprocedurestrainingcentresthroughcooperationwithlocalreputablehospitals.Thesetrainingcentreshaveprovidedsingle-portsurgerytrainingtodoctorsfromhospitalslocatedinmanyregionsacrossChina.Apartfromthis,wehavealsoparticipatedindifferentacademicconferencesandheldvideosurgerycompetitionstopromotemedicalknowledgeandadvocatestandardisedclinicaloperations. WewillcontinuetoexpandourR&Dteamandfocusonkeydevelopmentareasincludingbiodegradableimplantableconsumables,whichisoneofthemostimportantsegmentsinthemedicalfieldduetoitspotentialtohelpimprovingpatient’streatment.WeijingMedical,asubsidiaryoftheGroup,alsomadeprogressinitsR&Ddevelopment,andoneoftheremarkableachievementswasthelaunchofclinicaltrialforfour-armsurgicalrobotsinthefourthquarterof2023. Lookingahead,itisexpectedthatChina’shealthcareindustryandmarketwillcontinuetoexpandastheproportionoftheelderlypopulationinChinacontinuestosurge.Weareperseveringinimplementinglong-termstrategicplanning,focusingonthegrowthtrendinindustrydevelopment,strivingtoseizetheopportunitiesofimportsubstitutionandVBPs,expandingintotheinternationalmarketwithenormouspotential,andexploringinnovativeideasforChina’smedicaldeviceindustrytoleapforward.Themedicalindustryiscloselylinkedtopeople’shealthyliving.Weexpectthattheindustrywillgraduallyresumeitsnormaloperatinglevelsinthesecondhalfof2024,whichwillbeconducivetothelaunchofnewproductsandstrengthenface-to-faceacademicexchanges.Weareactivelyincreasingthemarketshareofourexistingcoreproducts.Atthesametime,wearealsocontinuouslyexpandingthegeographicalpresenceofnewproducts,includingultrasonicscalpels,4Kendoscopiccamerasystemsanddisposableproducts.Weareconfidentthatwewillbeabletoachieverelativelyhighgrowthratesofnewproductsin2024. OnbehalfoftheBoardofDirectors,IwouldliketoextendmysinceregratitudetoourShareholdersandsincerelythankourmanagementteamandemployeesfortheirhardwork.TheCompanywillactivelyexecutethedevelopmentstrategies,tocreategreatervalueforShareholdersthroughsustainablebusinessdevelopmentandcontinuousimprovementofcorporatemanagement,andtorewardthetrustofourShareholders. 2议0及23培年训，，我这们些成活功动策涵划盖了多专个题聚学焦术点推，广包会括产域专品题专会题议活。动例、如外，科我专们科透培过训与以当及地临知床名领医院中合心作已，为成中立国单多孔个手地术区培的训医中院心医。生该提等供培单训孔举手行术手培术训视。频此比外赛，活我动们，亦以参推与广学医术学会知议识及 术机器人临床试验。 及倡导规范化临床操作。 我领域们，持其续中扩包大括研可发降团解队植，入专耗注材于，关这键是发医展疗领患域者中治非疗常成重效要的的潜板力。块本，集因团为旗其下具唯有精改医善疗要的成研就发是工于作2也02取3年得第了四进季展度，其展中开一四项臂重手 展升，望中将国来的，随医着疗中保国健老行年业人市口场比预例计持将续持上续呈远战现略增规长划态，势瞄。准我行们业正发锲展而中不的舍增地长推趋进势长，致会，力拓把展握庞进大口的替国代际及市场集，中为带中量国采医购疗的器机械行生活业紧的密跃联进系探。路我。们医预疗期行该业行与业
